Literature DB >> 16192817

Early esophageal cancer: pattern of lymphatic spread and prognostic factors for long-term survival after surgical resection.

Hubert J Stein1, Marcus Feith, Bjorn L D M Bruecher, Jorg Naehrig, Mario Sarbia, J Rudiger Siewert.   

Abstract

OBJECTIVE: The objective of this study was to assess the prevalence and pattern of lymphatic spread in patients with early squamous cell and adenocarcinoma and identify prognostic factors for long-term survival after resection and lymphadenectomy. SUMMARY BACKGROUND DATA: Limited endoscopic approaches without lymphadenectomy are increasingly applied in patients with early esophageal cancer.
MATERIAL AND METHODS: A total of 290 patients with early esophageal cancer (157 adenocarcinoma, 133 squamous cell cancer) had surgical resection with systematic lymphadenectomy. Specimens were assessed for prevalence and pattern of lymphatic spread. Prognostic factors were determined by multivariate analysis.
RESULTS: None of the 70 patients with adenocarcinoma limited to themucosa had lymphatic spread, as compared with 2 of 26 with mucosal squamous cell cancer. Lymphatic spread was more common in patients with submucosal squamous cell cancer as compared with submucosal adenocarcinoma (36.4% versus 20.7%). Although lymph node metastases were usually limited to locoregional lymph node stations in early adenocarcinoma, distant lymphatic spread was frequent in early squamous cell cancer. On multivariate analysis, only histologic tumor type and the presence of lymph node metastases were independent predictors of long-term survival. Five-year survival rate was 83.4% for early adenocarcinoma versus 62.9% for early squamous cell cancer and 48.2% versus 79.5% for patients with/without lymphatic spread. DISCUSSION: Prevalence and pattern of lymphatic spread as well as long-term prognosis differ markedly between early esophageal squamous cell and adenocarcinoma. Limited resection techniques and individualized lymphadenectomy strategies appear applicable in patients with early adenocarcinoma.

Entities:  

Mesh:

Year:  2005        PMID: 16192817      PMCID: PMC1402356          DOI: 10.1097/01.sla.0000184211.75970.85

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  49 in total

Review 1.  Endoscopic mucosal resection as a staging technique to determine the depth of invasion of esophageal adenocarcinoma.

Authors:  Mary S Maish; Steven R DeMeester
Journal:  Ann Thorac Surg       Date:  2004-11       Impact factor: 4.330

2.  Accuracy of staging in early oesophageal cancer using high resolution endoscopy and high resolution endosonography: a comparative, prospective, and blinded trial.

Authors:  A May; E Günter; F Roth; L Gossner; M Stolte; M Vieth; C Ell
Journal:  Gut       Date:  2004-05       Impact factor: 23.059

3.  Intraepithelial high-grade neoplasia and early adenocarcinoma in short-segment Barrett's esophagus (SSBE): curative treatment using local endoscopic treatment techniques.

Authors:  A May; L Gossner; O Pech; H Müller; M Vieth; M Stolte; C Ell
Journal:  Endoscopy       Date:  2002-08       Impact factor: 10.093

4.  Histological analysis of endoscopic resection specimens from 326 patients with Barrett's esophagus and early neoplasia.

Authors:  M Vieth; C Ell; L Gossner; A May; M Stolte
Journal:  Endoscopy       Date:  2004-09       Impact factor: 10.093

5.  Long-term results of operation for 420 patients with early squamous cell esophageal carcinoma discovered by screening.

Authors:  Guo-Qing Wang; Guang-Gen Jiao; Fu-Bao Chang; Wei-Hong Fang; Jin-Xiang Song; Ning Lu; Dong-Mei Lin; Yong-Qiang Xie; Ling Yang
Journal:  Ann Thorac Surg       Date:  2004-05       Impact factor: 4.330

Review 6.  Approach to early Barrett's cancer.

Authors:  Hubert J Stein; Marcus Feith; Burkhard H A von Rahden; J Rüdiger Siewert; Burkhard A H v Rahden
Journal:  World J Surg       Date:  2003-08-18       Impact factor: 3.352

7.  Cervical, mediastinal, and abdominal lymph node dissection (three-field dissection) for superficial carcinoma of the thoracic esophagus.

Authors:  H Kato; Y Tachimori; S Mizobuchi; H Igaki; A Ochiai
Journal:  Cancer       Date:  1993-11-15       Impact factor: 6.860

8.  Local endoscopic therapy for intraepithelial high-grade neoplasia and early adenocarcinoma in Barrett's oesophagus: acute-phase and intermediate results of a new treatment approach.

Authors:  Andrea May; Liebwin Gossner; Oliver Pech; Andreas Fritz; Erwin Günter; Gerd Mayer; Hartmut Müller; Gerhard Seitz; Michael Vieth; Martin Stolte; Christian Ell
Journal:  Eur J Gastroenterol Hepatol       Date:  2002-10       Impact factor: 2.566

Review 9.  Surgical approach to invasive adenocarcinoma of the distal esophagus (Barrett's cancer).

Authors:  J Rüdiger Siewert; Hubert J Stein; Marcus Feith
Journal:  World J Surg       Date:  2003-08-21       Impact factor: 3.352

10.  Adenocarcinoma in Barrett's esophagus. A clinicopathologic study of 65 cases.

Authors:  J M Streitz; F H Ellis; S P Gibb; K Balogh; E Watkins
Journal:  Ann Surg       Date:  1991-02       Impact factor: 12.969

View more
  130 in total

Review 1.  Barrett's esophagus with high-grade dysplasia: focus on current treatment options.

Authors:  Leonidas Lekakos; Nikolaos P Karidis; Dimitrios Dimitroulis; Christos Tsigris; Gregory Kouraklis; Nikolaos Nikiteas
Journal:  World J Gastroenterol       Date:  2011-10-07       Impact factor: 5.742

2.  Barrett's Esophagus: A Review of Biology and Therapeutic Approaches.

Authors:  Panteleimon Kountourakis; Jaffer A Ajani; Marta Davila; Jeffrey H Lee; Manoop S Bhutani; Julie G Izzo
Journal:  Gastrointest Cancer Res       Date:  2012-03

Review 3.  Esophageal resection for high-grade dysplasia and intramucosal carcinoma: When and how?

Authors:  Vani J A Konda; Mark K Ferguson
Journal:  World J Gastroenterol       Date:  2010-08-14       Impact factor: 5.742

4.  Randomized controlled trial of laparoscopic gastric ischemic conditioning prior to minimally invasive esophagectomy, the LOGIC trial.

Authors:  Darmarajah Veeramootoo; Angela C Shore; Shahjehan A Wajed
Journal:  Surg Endosc       Date:  2012-02-01       Impact factor: 4.584

5.  Measurement of the tumor invasion depth into the submucosa in early adenocarcinoma of the esophagus (pT1b): Can microns be the new standard for the endoscopist?

Authors:  Hendrik Manner; Oliver Pech
Journal:  United European Gastroenterol J       Date:  2015-12       Impact factor: 4.623

6.  Clinical impact of lymphadenectomy extent in resectable esophageal cancer.

Authors:  Roderich E Schwarz; David D Smith
Journal:  J Gastrointest Surg       Date:  2007-09-02       Impact factor: 3.452

Review 7.  Minimally invasive surgery for esophageal cancer: a review on sentinel node concept.

Authors:  Bogdan Filip; Marco Scarpa; Francesco Cavallin; Rita Alfieri; Matteo Cagol; Carlo Castoro
Journal:  Surg Endosc       Date:  2013-11-27       Impact factor: 4.584

8.  Overall survival analysis of neoadjuvant chemoradiotherapy and esophagectomy for esophageal cancer.

Authors:  Faisal A Siddiqui; Katelyn M Atkins; Brian S Diggs; Charles R Thomas; John G Hunter; James P Dolan
Journal:  J Gastrointest Oncol       Date:  2014-04

9.  Risk of metastasis in adenocarcinoma of the esophagus: a multicenter retrospective study in a Japanese population.

Authors:  Ryu Ishihara; Tsuneo Oyama; Seiichiro Abe; Hiroaki Takahashi; Hiroyuki Ono; Junko Fujisaki; Mitsuru Kaise; Kenichi Goda; Kenro Kawada; Tomoyuki Koike; Manabu Takeuchi; Rie Matsuda; Dai Hirasawa; Masayoshi Yamada; Junichi Kodaira; Masaki Tanaka; Masami Omae; Akira Matsui; Takashi Kanesaka; Akiko Takahashi; Shinichi Hirooka; Masahiro Saito; Yosuke Tsuji; Yuki Maeda; Hiroharu Yamashita; Ichiro Oda; Yasuhiko Tomita; Takashi Matsunaga; Shuji Terai; Soji Ozawa; Tatsuyuki Kawano; Yasuyuki Seto
Journal:  J Gastroenterol       Date:  2016-10-18       Impact factor: 7.527

Review 10.  Endoscopic therapy for Barrett's esophagus and early esophageal adenocarcinoma.

Authors:  Cadman L Leggett; Emmanuel C Gorospe; Kenneth K Wang
Journal:  Gastroenterol Clin North Am       Date:  2013-03       Impact factor: 3.806

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.